US EditionPublished • loading... • Updated
Cizzle Biotechnology To Validate CIZ1B Lung Cancer Test Through NHS-linked Partnership
Summary by DirectorsTalk Interviews
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Cizzle Biotechnology To Validate CIZ1B Lung Cancer Test Through NHS-linked Partnership
Cizzle Biotechnology Holdings plc (LON:CIZ) Chairman Derek Bickerstaff caught up with DirectorsTalk to discuss the company’s new letter of intent with an NHS-affiliated diagnostics partner to validate and commercialise the CIZ1B early cancer test. Q1: You have announced the signing of a Letter of Intent with a leading medical diagnostic service provider acting in partnership with the NHS. Can you just explain for us what the Letter of Intent cov…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
